Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
CEO spoke of a possible 2 month impact on the supply chain, with normalization afterwards. If we get confirmation this month that ML2 is up and running again, I see no reason why we should not hold on. In the other scenario it will become problematic.
In the kanaal Z video they mention: "in 2021 H1 we increased our R&D efforts a lot , in the future we will invest at a slower pace.
It is simple economics, you can only become profitable if money coming in > the money going out. Temporarily lowering cost in R&D, together with a cost reduction in the production process, and selling more product at a good price is the way to go. The sooner you reach that point of break even, the better. BCART is reaching that critical point where they have to show they are able to do that.
El Torro A few weeks ago I posted a point Cathy Wood of Ark made about Wrights Law. It dictates that the cost of production of a product should drop by a set amount for each doubling of product output. Wood indicates that the reduction should be 25 to 30% for genomics and automation businesses, I was really looking for evidence of this scaling becomming apparent in BCARTs gross margins as production ramped on ML2. Being from the US it is frustraiting because financial results in the EU are presented semiannually. rather than quarterly. So there are less data points to track this progress. The 9-2 presentation claimed one off reasons resulted in failure to acheive margin improvements (mostly reagent availability restricting ML2 ramp). We are now asked to believe that this problem will be resolved despite the loss of reagents in the fire. We are already seeing investor patience wearing thin. Verrelst need to provide a creditable explanation as to how this will be corrected. FL
Mogelijke doorbraak in cartridge productie, nieuw vereenvoudigd/kosten efficiënt cartridge ontwerp. Aanzienlijk lagere productiekosten voor selectie Idylla tests & nieuwe technologie op Idylla voor personalisatie Idylla tests, lagere ontwikkelingstijd/kost . Cruciale ontwikkeling voor duurzame groei de komende jaren 2021; Cartridges +40%?Waar er eerder een range van 40-60% was. 1/Basic covid testing in USA zal(zoals voorzien)dalen in HJ 2 2021. 2/Groeiseizoen wordt in HJ 1 2022 verwacht. 3/Reagentia op tijd zodanig dat ML2 op tijd kan starten,2 de helft september. Idylla;300-350 geplaatst,Min 50 milj in kas op voorwaarde dat de verzekering op tijd uitkeert. Kleine uitstel op vooruitgang menu omdat men die wil lanceren met nieuwe Cartridges. Waiting feedback FDA MSI test; Verwacht voor komende maanden. ML3?;Eerst gat ze ML1 &ML2 volledig benutten (capaciteit samen 1,4 miljoen Cartridges)2021 ;320000? Maw.ML3 is nog niet aan de orde, Verder zou een nieuwe lijn binnen het jaar kunnen functioneren. Hoe het je bekijkt, het glas is halfvol of halfleeg.,
2/Groeiseizoen=Griepseizoen.
-- [i]China en Japan -- In China en Japan werd verdere vooruitgang geboekt. Registratie van het Idylla(TM) instrument in China wordt verwacht tegen eind dit jaar, terwijl registratie van Idylla(TM) tests ten vroegste eind 2022 zullen volgen voor beide landen. Voorts verliep in H1 2021 de vooruitgang bij de lokale productie in China voorspoedig; de lokale productie van de eerste cartridgevolumes nodig voor de lokale registratie van de tests wordt verwacht in H1 2022. De lokale productie in China wordt volgens dit bericht verwacht in H1 2022: is dat dan niet op die ML3 ? De eerste cartridges dienen voor lokale registratie, wat de logische gang van zaken is. Dit bericht lijkt mij te bevestigen dat de productielijn in China nu al in opbouw is. Of lees ik dit verkeerd?
Dr Zoot I don't think that you are reading anything wrong. I have the same take away that ML3 is already under construction. Assuming that Wondfo and BCART each kick in 50%, then BCART has already started contributing part of the estimated 10 million required to set up ML3. They really seem to intentionally underplay the progress reports from China.. I was under the impression that the consoles were already registered or that registration had been waived in China since WondfoCartis sells the units without listing them as RUO, the way the cartridges are designated. FL
If Biocartis has already started setting up the ML3 production line (agreed), why is such an important positive story not mentioned more explicitly in their mid-year update? It could certainly help to support the disappointing share price evolution. We are now back at 4.01€.
Verrelst indicated a couple years ago. when ML2 was under construction that the next line (ML3) would be faster and cheaper since the designs and fabricators had been identified, However, now they claim that they are contemplating a breakthrough that would significantly lower production costs. If this breakthrough will reduce costs so significantly you would think they would incorporate it into ML3. I think they have done preliminary work on the structure but have not commenced on setting up the portions of the line that could be affected by the changes. All just guesses since they provide few details, FL
The Verrelst interview from a couple years indicated that the 3rd line could be constructed quicker and cheaper than the 2nd line since the designs had been completed and the vendors could recreate the equipment quickly. However, on 9-2 they indicated they were nearing a breakthrough that could significantly lower production costs. It would seem that they would want to incorporate these changes into line ML3. So while we know the timeline that it needs to be operational in H1- 22 so the registration can proceed in China. I think you're right that some discussion was probably warranted, especially since it helps to explain the increased cash burn (I'm assuming BCART pays 50% and Wondfo the other 50%). BCART has steered clear of discussing China in much detail, either because they don't want to box in government regulators or because they don't want to tip off competition. FL
Dr Zoot schreef op 6 september 2021 09:42 :
-- [i]China en Japan -- In China en Japan werd verdere vooruitgang geboekt.
Registratie van het Idylla(TM) instrument in China wordt verwacht tegen eind dit jaar, terwijl registratie van Idylla(TM)
tests ten vroegste eind 2022 zullen volgen voor beide landen.
Voorts verliep in H1 2021 de vooruitgang bij de lokale productie in China voorspoedig; de lokale productie van de eerste
cartridgevolumes nodig voor de lokale registratie van de tests wordt verwacht in H1 2022.
De lokale productie in China wordt volgens dit bericht verwacht in H1 2022: is dat dan niet op die ML3 ? De eerste cartridges dienen voor lokale registratie, wat de logische gang van zaken is.
Dit bericht lijkt mij te bevestigen dat de productielijn in China nu al in opbouw is. Of lees ik dit verkeerd?
Kunnen ze geen cartridges maken/samenstellen in een labo ofzo zonder een productielijn? Zou mij sterk verbazen dat je een productielijn bouwt zonder over te communiceren... De eerste cartridges die ze hier maakten zullen toch ook niet direct op een productielijn gemaakt zijn.
De cartidges geproduceerd in China zijn m.i. exact dezelfde als deze die nu geproduceerd worden in België, dus hiervoor moet je geen extra productielijn bouwen in China. Een lokale productielijn in China is m.i. een noodzakelijke voorwaarde om daar testen gecertifieerd te krijgen voor vermarkting op de Chinese markt. Enkel cartridges geproduceerd op een lokaal gecertificeerde productielijn worden toegelaten. Maar vermoedelijk wordt het nadien wel mogelijk in China geproduceerde cartidges elders in de wereld te gebruiken. De kans is groot dat die een stuk goedkoper zullen zijn dan in Belgie geproduceerde exemplaren (met stevige premies voor nacht- en weekend werk, wat vermoedelijk in China niet geldt) Echter, ik heb grote verwachtingen van de aangekondigde "simplified cost effective manufacturing method under evaluation): hierbij worden in de geproduceerde cartridges enkel de generieke reagentia vloeistoffen toegevoegd (van toepassing voor alle Idylla gebaseerde tests) en de test specifieke reagentia nog niet. Die worden door de klant zelf toegevoegd al naargelang de test die zij uitvoeren. Dat betekent een enorme besparing in warehousing voor Biocartis: immers, in het oude systeem moet je per type test op basis van een sales forecast voorraad cartridges produceren per test, vermoedelijk met een beperkte houdbaarheid per test type. Nu worden alle cartridges identiek (enkel met de basis reagentia) en allles compatiebel met bestaande installed base equipment.
Dr Zoot The system you describe sounds interesting but I'll be curious how the finishing reagents are added without compromising the sealed, free from DNA cross contamination that is presently claimed. Finding a cheaper way to manufacture cartridges seems critical to BCARTs long term survival. FL
One more reason for the decreased gross margins during the 1st half. Although BCART did not discuss it, the sales revenue from the US was very low (about the same as the UK). The relative market mix with the US (a high priced market) comprising a lower percentage of the sales undoubtedly played a large role in the margin erosion. They attributed it to hospital budgets constrained by COVID, I think this is incorrect. The government has flooded the public sector in the US with liquidity. As I've said before, the RUO probably comprises less than 10% of the hospitals in the US, Most RUO environments are associated with university health complexes or are reliant on grad student staffing of labs. So, when almost all of your products are designated RUO, it is a huge constraint, Most universities in the US were under COVID lockdown and teaching remotely during the 1st half. Therefore, many research assistants were not in the labs, so much of the RUO market was non-existent.or severely limited. Most universities have reopened and research labs should be functional in the 2nd half. So I think the numbers will look better, assuming the fire constrained supply can be re-established. More importantly, I believe this situation drives home the importance of the registrations. MSI and Septicyte are pending FDA approval. These approvals any many other assay approvals are necessary to open the use of Idylla to the wider universe of facilities outside of the RUO setting. The increase in Idylla use in the EU where the number of IVD registrations is greatest demonstrate that labs can use the Idylla flexibility to meet testing demands since they promote distancing etc. Due to the RUO restriction, Idylla cannot be used in this manner in the US. FL
Indeed FL, we are still awaiting the approvals in US... I do not understand why this is taking so long.
Sepsis September;het is eens tijd dat die test wordt goedgekeurd. "Sepsis takes a live every 2 minutes". Waar wachten ze eigenlijk op?
FL To be honest, I don't have the answer to your question regarding the additional contamination risk caused by off-line filling of the bio-marker specific reagents. I guess a peristaltic pump to fill the pre-sealed empty slot in the cartridge should go a long way. Interestingly, Biocartis doesn't only mentions cost savings, but also shorter development time as one of the advantages. (Simplified certification process without re-certification of generic components for the sample preparation and biomarker detection? not sure) The text reads: The VLAIO grant is intended to support the ongoing development of a new Idylla™ technology, which will enable the off-line customization of the Idylla™ cartridge. The first generation Idylla™ cartridges contain not only the generic components for sample preparation and biomarker detection, but also the biomarker-specific reagents. The next generation Idylla™ cartridges on the other hand would only contain the generic components for sample preparation and biomarker detection, and would be made biomarker-specific through the addition by the user of a ready-to-use mixture containing biomarker-specific reagents. This new Idylla™ technology would be fully compatible with the current Idylla™ cartridge manufacturing lines and installed base, and is expected to further reduce the Idylla™ assay development time and cost.
Dr Zoot, I think it is a concern but is definitely not insurmountable. Labs are used to procedures that minimize or eliminate potential for cross contamination. My guess is that the assay specific reagents will be introduced through a kit containing pre-filled syringes or similar device. The reagents currently used are in a freeze dried state, largely because they have longer shelf life, so there may be a constraint that the assay must be run in a relatively short time following the addition of the assay specific reagents. Hopefully, there won't be any IVD registration approval issues, for assays that already have full IVD approval. Regards FL
Flat I think your right about the RUO , it’s a big problem for penetration in the US . But to my understanding for the COVID test there were no restrictions. So again with uncountable PCR test performed worldwide they suceed in not getting a slice of that pie. They need urgently a commercial service that starts selling the systems , if you have that kind of technological advantage and after the pandemic is gone they can be used in oncologie. Finally for those who think the new construction of the cassettes would be the holy grale, the current cassettes are not yet FDA approved after how many years so excuse me to have a little doubt .
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee